AtriCure (NASDAQ:ATRC) Stock Rating Lowered by Freedom Capital

AtriCure (NASDAQ:ATRC) was downgraded by Freedom Capital from a “strong-buy” rating to a “hold” rating in a report issued on Friday, Zacks reports.

A number of other research analysts also recently commented on the stock. Stifel Nicolaus set a $65.00 target price on shares of AtriCure in a research report on Thursday, September 17th. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, BTIG Research boosted their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $53.30.

AtriCure Trading Up 2.9%

NASDAQ ATRC opened at $55.14 on Friday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure has a 52 week low of $25.36 and a 52 week high of $61.70. The stock has a market capitalization of $2.80 billion, a PE ratio of 262.58 and a beta of 1.24. The firm has a 50 day moving average of $49.44 and a two-hundred day moving average of $36.38.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Salvatore Privitera sold 4,519 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total value of $271,140.00. Following the sale, the insider directly owned 142,745 shares of the company’s stock, valued at approximately $8,564,700. This represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 74,868 shares of company stock valued at $3,317,897. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Large investors have recently bought and sold shares of the company. Man Group plc acquired a new position in shares of AtriCure during the second quarter worth about $684,000. Bank of America Corp DE raised its holdings in AtriCure by 13.7% during the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after purchasing an additional 92,830 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in AtriCure in the second quarter valued at about $699,000. WINTON GROUP Ltd acquired a new stake in AtriCure in the second quarter valued at about $1,002,000. Finally, Assenagon Asset Management S.A. purchased a new stake in AtriCure in the 2nd quarter valued at approximately $1,744,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.